The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19 antiviral pill Paxlovid. 

“There is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected,” CDC said, noting that a brief return of symptoms may be part of the natural history of SARS-CoV-2 infection in some individuals, “independent of treatment with Paxlovid and regardless of vaccination status.”

CDC continues to recommend Paxlovid to treat mild to moderate COVID-19 in patients at high risk for progressing to severe disease and isolating patients when COVID-19 rebounds to manage transmission risk.

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration this week…
Headline
The Centers for Disease Control and Prevention last night endorsed Moderna’s COVID-19 vaccine for children aged 6-17, as its advisory committee…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today unanimously recommended Moderna’s COVID-19 vaccine for…
Headline
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices on Saturday recommended the Moderna vaccine for children aged 6…
Headline
The Food and Drug Administration today authorized Moderna’s COVID-19 vaccine for children aged 6 months through 17 years old and Pfizer’s COVID-19 vaccine for…
Headline
A Food and Drug Administration advisory committee today recommended the agency authorize Moderna’s COVID-19 two-dose vaccine for children aged 6 months…